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Abstract
Background: S100A7 is an antimicrobial peptide involved in several inflammatory diseases. The aim of the present
study was to explore the expression and regulation of S100A7 in seasonal allergic rhinitis (SAR).
Methods: Nasal lavage (NAL) fluid was obtained from healthy controls before and after lipopolysaccharide (LPS)
provocation, from SAR patients before and after allergen challenge, and from SAR patients having completed
allergen-specific immunotherapy (ASIT). Nasal biopsies, nasal epithelial cells and blood were acquired from healthy
donors. The airway epithelial cell line FaDu was used for in vitro experiments. Real-time RT-PCR and
immunohistochemistry were used to determine S100A7 expression in nasal tissue and cells. Release of S100A7 in
NAL and culture supernatants was measured by ELISA. The function of recombinant S100A7 was explored in
epithelial cells, neutrophils and peripheral blood mononuclear cells (PBMC).
Results: Nasal administration of LPS induced S100A7 release in healthy non-allergic subjects. The level of S100A7
was lower in NAL from SAR patients than from healthy controls, and it was further reduced in the SAR group 6 h
post allergen provocation. In contrast, ASIT patients displayed higher levels after completed treatment. S100A7 was
expressed in the nasal epithelium and in glands, and it was secreted by cultured epithelial cells. Stimulation with
IL-4 and histamine repressed the epithelial S100A7 release. Further, recombinant S100A7 induced activation of
neutrophils and PBMC.
Conclusions: The present study shows an epithelial expression and excretion of S100A7 in the nose after microbial
stimulation. The levels are diminished in rhinitis patients and in the presence of an allergic cytokine milieu,
suggesting that the antimicrobial defense is compromised in patients with SAR.
Keywords: allergen-specific immunotherapy, antimicrobial peptide, epithelium, lipopolysaccharide, seasonal allergic
rhinitis, Th2 cytokines
Background
S100A7, also known as psoriasin, belongs to the S100
protein family consisting of ~20 different EF-hand type
proteins [1]. It was first identified as highly up-regulated
in the skin of psoriatic patients [2], but has also been
attributed a role in atopic dermatitis (AD) and different
types of cancer, including skin, breast and bladder can-
cer [3-6]. The function of S100A7 is still poorly
understood, but several studies suggest that it acts both
as an antimicrobial peptide (AMP) and as a chemotactic
factor for neutrophils and CD4
+ T cells [7-9]. In addi-
tion, S100A7 has been shown to directly kill bacteria
and protect human skin from E. coli infection [7], and
to activate neutrophils to produce a range of cytokines,
chemokines, AMPs and reactive oxygen species [10].
Although S100A7 has been linked to atopic dermatitis,
there is little information available regarding its role in
o t h e ra t o p i cd i s e a s e s .W eh a v ep r e v i o u s l ys h o w nl o w e r
levels of S100A7 in nasal lavage (NAL) fluid from
patients with pollen-induced seasonal allergic rhinitis
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with lower S100A7 mRNA levels in tonsils obtained
from allergic as compared to healthy donors [12]. More-
over, by analyzing the genetic variation in the S100A7
gene, we have described a SNP (rs3014837), which gives
rise to a Asp ® Glu amino acid shift, that is associated
with the occurrence of SAR [13]. In addition, Tieu et al.
have recently demonstrated diminished levels of S100A7
in NAL fluids from patients with chronic rhinosinusitis
(CRS) and SAR, along with a less intense epithelial
S100A7 staining in sinonasal tissue extracts from CRS
patients compared to control samples [14]. Previous stu-
dies suggest the epithelium to be the main cellular
source of S100A7 in the nose [14,15], but the mechan-
isms regulating its differential expression in airway
inflammation have not yet been established. Therefore,
the purpose of the present study was to further evaluate
the expression of S100A7 in the nose and to investigate
its regulation in SAR.
Methods
Subjects
The study was approved by the local Ethics Committee
and all participants gave their written informed consent.
A detailed description of the subjects included is pre-
sented in Table 1. NAL fluids were obtained from i) 13
healthy subjects before and 24 h after nasal LPS admin-
istration; ii) 12 patients with SAR before and 6 h after
allergen provocation; and iii) 10 SAR patients prior to
and 3 years after completion of allergen-specific immu-
notherapy (ASIT) with a depot vaccine (Alutard
®,A L K
Abelló, Hørsholm, Denmark). Serum was acquired from
10 healthy volunteers and 12 patients with SAR. Nasal
biopsies were taken from 11 healthy volunteers.
All SAR patients had a history of birch and/or grass
pollen-induced rhinoconjunctivitis for at least 2 years
with moderate to severe symptoms and exhibited a posi-
tive skin prick test (SPT) to birch and/or timothy pollen
(wheal reaction diameter > 3 mm) as previously
described in detail [16]. Control subjects were all symp-
tom-free with no history of SAR and a negative SPT to
the standard panel of allergens. All participants were
free from medication ≥ 3 months prior to the study.
Subjects with a history or signs of CRS including nasal
polyposis were excluded along with patients with hyper-
trophy of turbinates, severe septum deviation or a his-
tory of airway infection within two weeks before the
first visit.
Lipopolysaccharide (LPS) and allergen provocation
Healthy subjects were sprayed with 100 μl of a 0.5 μg/μl
solution of LPS from E. coli (Sigma-Aldrich, St. Louis,
MO, USA) into each nostril, yielding a total of 100 μg
LPS [17]. Allergen provocation was performed by spray-
ing 10,000 SQ-U of birch or grass pollen extracts
(Aquagen, ALK Abelló) into each nostril. Nasal wash-
ings were performed prior to and after provocation.
Sample collection
All sampling was performed outside pollen season.
Blood samples were obtained in Vacuette
® serum tubes.
NAL fluid was acquired as previously described in detail
[18]. Briefly, after clearing excess mucus by exsufflation,
a sterile saline solution was aerosolized into both nos-
trils. Nasal fluids were passively collected using a graded
test tube until 7 ml was collected. After centrifugation
at 1750 rpm at 4°C for 10 min the supernatant was
separated from the cell pellet and collected. Nasal biop-
sies, approximately 2 × 2 × 2 mm in size, were taken
from the inferior turbinate after topical application of
local anaesthesia containing lidocaine hydrochloride:
nafazoline (34 mg/ml:0.17 mg/ml) for 20 min.
Airway epithelial cells (AEC)
The nasopharyngeal epithelial cell line FaDu was
obtained from ATCC (Manassas, VA, USA) and cul-
tured in Minimum Essential Medium (MEM) with Ear-
le’s salts and 2 mM L-glutamine (Gibco, Grand Island,
NY, USA) supplemented with 10% FBS (PAN biotech,
Aidenbach, Germany), 100 U/ml penicillin and 100 μg/
ml streptomycin (Gibco). Primary human nasal epithelial
cells (HNEC) were obtained by nasal brushings of 6
healthy non-smoking volunteers (4 males, 2 females, age
20-50) as previously described in detail [19]. HNEC
were cultured in collagen-coated tissue culture flasks in
airway epithelial cell growth medium supplemented with
Table 1 Patient characteristics.
Treatment n Samples Sex Age, median (range)
Healthy subjects LPS 13 NAL 5 M, 8 F 27 (22-47)
SAR patients allergen 12 NAL, serum 6 M, 6 F 29 (19-47)
SAR patients ASIT 10 NAL 7M, 3 F 31 (15-36)
Healthy subjects - 10 serum 2 M, 8 F 27.5 (23-48)
Healthy subjects - 11 biopsies 5 M, 6 F 38 (20-50)
Healthy subjects - 6 HNEC 4 M, 2 F 37 (25-48)
ASIT, allergen-specific immunotherapy; F, females; HNEC, human nasal epithelial cells; M, males; NAL, nasal lavage; SAR, seasonal allergic rhinitis
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growth factor, 5 μg/ml insulin, 0.5 μg/ml hydrocorti-
sone, 0.5 μg/ml epinephrine, 6.7 ng/ml triiodothyronine,
10 μg/ml transferrin, 0.1 ng/ml retinoic acid (PromoCell,
Heidelberg, Germany), 100 U/ml penicillin and 100 μg/
ml streptomycin (Gibco) [20]. All cells were cultured at
37°C in a humidified 5% CO2 air atmosphere.
FaDu cells were seeded on 24-well culture plates
(250,000 cells/well) in 1 ml complete MEM and incu-
bated overnight. Thereafter, they were cultured for addi-
tionally 24 h in the absence or presence of recombinant
human IL-4 (R&D Systems, Minneapolis, MN, USA),
histamine (Sigma-Aldrich) or S100A7 (ProtEra, Sesto
Fiorentino, Italy).
Isolation and culture of cells from peripheral blood
Peripheral blood was acquired from healthy volunteers,
diluted 1:1 in PBS and centrifuged using Ficoll-Paque
(Amersham Bioscience, Uppsala, Sweden). Peripheral
blood mononuclear cells (PBMC) were retrieved from
the interphase fraction, whereas granulocytes were
recovered from the pellet. Briefly, the granulocyte-rich
pellet, containing ≥ 90% neutrophils, was treated with
an ammonium chloride lysis buffer to remove erythro-
cytes, followed by collection of neutrophils. Eosinophils
were negatively selected from granulocytes using the
MACS magnetic labeling system (Eosinophil Isolation
Kit, Miltenyi Biotec, Cologne, Germany) as previously
described in detail [21]. The interphase fraction after
centrifugation was washed, and monocytes were isolated
using CD14 Microbeads (Miltenyi Biotec). B and T lym-
phocytes were negatively selected using the B cell Isola-
tion Kit II and Pan T cell Isolation Kit II [22,23],
respectively (Miltenyi Biotec).
PBMC (1 × 10
6 cells/ml) and neutrophils (4 × 10
6
cells/ml) were cultured in RPMI 1640 supplemented
with 0.3 g/l L-glutamine (PAA, Pasching, Austria), 10%
FBS, 100 U/ml streptomycin and 100 μg/ml penicillin in
the absence or presence of rhS100A7. After various time
points, cytokine levels in the supernatants were analyzed
using ELISA, proliferation was measured by [methyl-
3H]
thymidine incorporation and expression of the adhesion
molecule CD11b was determined using flow cytometry.
Immunohistochemistry
The presence of S100A7 protein in the nose was
assessed using immunohistochemical staining. Nasal
biopsies were fixed in 4% buffered formaldehyde for 7
days, thereafter processed and embedded in paraffin.
Sections (3 μm thick) were cut, dried for 2 h at 60°C
and then stored at 4°C until further use. The tissue sec-
tions were deparaffinized in xylene and then rehydrated
through graded alcohol and deionized water. For antigen
retrieval the sections were processed in a microwave
oven in target retrieval solution with a pH of 6.1 (Dako,
Glostrup, Denmark). A mouse anti-human S100A7 anti-
body (clone 47C1068) from Abcam (Cambridge, UK)
was used at a dilution of 1:100. As negative control, N-
series Universal Negative Control Reagent against
mouse (Dako) was utilized. The staining procedure was
performed in a Techmate 500 Plus immunostaining
machine according to standard “ENVP” procedure
(Dako). The sections were counterstained with hematox-
y l i n ,d e h y d r a t e di ng r a d e da l c o h o l ,p a s s e dt h r o u g h
xylene and mounted.
RNA extraction and real-time RT-PCR
Nasal biopsies, epithelial cells and freshly isolated leuko-
cytes were lysed in RLT buffer (Qiagen, Hilden, Ger-
many) supplemented with 1% 2-mercaptoethanol and
stored in -80°C until use. Total RNA was extracted
using RNeasy Mini Kit (Qiagen), and the quantity and
quality of the RNA were measured by spectrophotome-
try using the wavelength absorption ratio (260/280 nm).
Reverse transcription of total RNA into cDNA was per-
formed using the Omniscript™ reverse transcriptase kit
(Qiagen) with oligo(dT)16 primer (DNA Technology A/
S, Aarhus, Denmark) in a Mastercycler personal PCR
machine (Eppendorf AG, Hamburg, Germany). The
reaction was carried out at 37°C for 1 h.
The real-time PCR reactions were performed on a Stra-
tagene Mx3000P (Agilent Technologies, Santa Clara, CA,
USA) using the Brilliant
® II SYBR
® Green QPCR Master-
mix (Agilent Technologies) in a final volume of 20 μl. The
PCR primers (b-actin fwd: 5’-GCCAACCGCGAGAA-
GATG-3’,r e v :5 ’ACGGCCAGAGGCGTACAG-3’;
S100A7 fwd: CGTGACGCTTCCCAGCTC-3’,r e v :5 ’-
TCATCACGTCTGGTGTATTTGTGA-3’) were designed
using Primer Express
® 2.0 Software (Applied Biosystems,
Foster City, CA, USA) and synthesized by DNA Technol-
ogy [12]. The thermal cycler was set to perform 95°C for
15 min, followed by 46 cycles of 94°C for 30 s and 55°C
for 60 s (initially 65°C, followed by a 2°C decrease for the
six first cycles). Melting curve analysis was performed to
ensure specificity of the amplified PCR products. The
mRNA expression was assessed using the comparative
cycle threshold (Ct) method where the relative amounts of
mRNA were determined by subtracting the Ct value of
S100A7 with Ct values of b-actin (ΔCt). The amount of
mRNA is expressed as 2
-ΔCt ×1 0
5 [19-23].
Flow cytometry
Cultured neutrophils were stained with CD16-ECD
(clone 3G8) and CD11b-FITC (Bear1) (Beckman Coul-
ter, Marseille, France) for 15 min in RT. Thereafter,
cells were washed, resuspended in PBS and analyzed on
a Coulter Epics XL flow cytometer (Beckman Coulter).
Neutrophils were distinguished based on their forward
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their expression of CD16, as FSc
high,S S c
high,C D 1 6
+.
10,000-15,000 events were collected and analyzed using
Expo32 ADC analysis software (Beckman Coulter).
ELISA
Levels of S100A7 in unprocessed NAL fluid, serum and
culture supernatants were detected using the Circulex™
S100A7/Psoriasin ELISA kit (detection limit 0.12 ng/ml)
from MBL International (Woburn, MA, USA). ELISA
plates to measure IL-1b (1 pg/ml), IL-6 (0.7 pg/ml), IL-8
(3.5 pg/ml) and IL-10 (3.9 pg/ml) in cell culture super-
natants were obtained from R&D Systems.
Statistics
Statistical analyses were performed using GraphPad
Prism 5 (San Diego, CA, USA). All data are presented
as mean ± standard error of the mean (SEM), and n
equals the number of independent donors. For unpaired
data, statistical differences were determined using
unpaired Student’s t-test with Welch correction if the
variances were non-homogenous. Paired observations
were analyzed using paired t-test (for two sets of data)
or one-way repeated measures ANOVA with Dunnett’s
post test (> 2 sets of data). A p-value of < 0.05 was con-
sidered statistically significant.
Results
Nasal LPS administration induces release of S100A7
To investigate whether microbial exposure affects the
nasal release of S100A7, healthy non-allergic subjects
were exposed to nasal administration of the prototypical
inflammatory stimulus LPS. NAL fluids were collected
before and 24 h post challenge followed by measure-
ments of S100A7 by ELISA. LPS was found to increase
the S100A7 excretion (Figure 1).
Levels of S100A7 in NAL fluid are lower in patients with
SAR and decrease after allergen provocation
NAL fluids and serum from healthy subjects and SAR
patients outside season were analyzed for levels of
S100A7 by use of ELISA. A significantly lower baseline
S100A7 release in the nose was seen in the allergic as
compared to the healthy group (Figure 2A), whereas no
difference was found in serum (4.5 ± 0.9 vs. 3.7 ± 0.5
ng/ml; p = 0.74). Thereafter, we wanted to investigate
the effects of allergen provocation on nasal S100A7
secretion in the allergic group. It was found that the
S100A7 levels were significantly lower 6 h post provoca-
tion as compared to before (Figure 2B).
Levels of S100A7 increase in SAR patients after ASIT
The diminished levels among allergics led us to investi-
gate whether SAR patients that have completed ASIT
treatment still have a deficient S100A7 production or
whether they have acquired levels comparable to those
of healthy individuals. NAL fluid was collected from 10
patients before and after ASIT and analyzed for baseline
levels of S100A7 by use of ELISA. Immunotherapy treat-
ment increased the generation of S100A7 in nine out of
the ten donors examined (Figure 2C).
S100A7 is produced by nasal epithelial cells
To ascertain the presence of S100A7 in the nose, immu-
nohistochemistry and real-time RT-PCR were performed
on nasal biopsies obtained from healthy donors. An
intense immunostaining was seen in seromucous glands
and in the epithelium (Figure 3A, B), whereas replace-
ment of the primary specific antibody with an isotype-
matched control antibody resulted in complete loss of
staining (Figure 3C). Expression of S100A7 mRNA was
found in all biopsy specimens (Figure 3D).
The cellular sources of S100A7 were further investi-
gated in primary HNEC, the nasopharyngeal epithelial
cell line FaDu and isolated leukocytes that can be found
in the epithelial and subepithelial regions. A distinct
mRNA expression was seen in HNEC, but also in FaDu
(Figure 3D), and secreted S100A7 could be detected in
the cell culture medium from both AECs (Figure 3E).
Low levels of S100A7 mRNA were also found in B cells,
monocytes and neutrophils, whereas there was no
expression in T cells or eosinophils (Figure 3F).
Figure 1 Nasal administration of LPS induces S100A7 release.
Healthy subjects were exposed to nasal administration of LPS (100
μg). Nasal lavage (NAL) fluids were obtained before and 24 h post
LPS challenge, followed by measurements of S100A7 by use of
ELISA (n = 13). *, p < 0.05 (paired t-test).
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fluids obtained from healthy subjects (n = 13) and patients with seasonal allergic rhinitis (SAR, n = 12). **, p < 0.01 (unpaired t-test). (B) Levels
of S100A7 in NAL fluid from patients with SAR before and 6 h after allergen provocation (n = 12). ***, p < 0.001 (paired t-test). (C) Baseline levels
of S100A7 in NAL fluid obtained from patients with SAR before and 3 years after allergen-specific immunotherapy (ASIT, n = 10). *, p < 0.05
(paired t-test).
Figure 3 S100A7 is present in the nasal epithelium and seromucous glands. Tissue slides of the human inferior turbinate were stained with
(A, B) a monoclonal antibody against S100A7 or (C) an isotype-matched control antibody. Positive staining (brown) was detected in the nasal
epithelium and in seromucous glands. Counterstaining with hematoxylin (blue) (magnification 100 ×). (D) Expression of S100A7 mRNA was
determined in nasal biopsies (n = 11), primary human nasal epithelial cells (HNEC, n = 6) and FaDu (n = 4) by real-time RT-PCR. Data is
expressed in relation to b-actin as 2
-ΔCt ×1 0
5. (E) Levels of S100A7 in the culture medium from HNEC and FaDu were analyzed by ELISA (n = 4-
6). (F) mRNA expression of S100A7 in purified peripheral blood T lymphocytes, B lymphocytes, monocytes, neutrophils and eosinophils using
real-time RT-PCR (n = 3-6). Data are presented as mean ± SEM.
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T os t u d yt h er e g u l a t i o no fS 1 0 0 A 7i nt h en o s ea n d
elucidate the mechanisms behind the diminished levels
during SAR, we hypothesized that it might be con-
sumed during the allergic inflammation by the infil-
trating cells. The target cells for secreted S100A7 in
the nose are not fully identified, but the reported che-
motactic properties for CD4
+ T cells and neutrophils
[8] suggest that it is aimed for the latter as neutrophils
are the most abundant cell type in nasal washings [24].
The number of neutrophils in NAL fluid was signifi-
cantly higher in the allergic as compared to the healthy
group (6.4 ± 1.8 vs. 1.6 ± 0.7 × 10
4 cells/ml; p < 0.05),
whereas allergen provocation did not alter the number
of cells (5.7 ± 0.8 vs. 6.4 ± 1.8 × 10
4 cells/ml; p =
0.70). However, no correlation between neutrophil
numbers and S100A7 levels was found (r
2=0 . 0 5 5 ;
Pearson r = -0.235; p = 0.21).
Instead, we asked whether mediators produced dur-
ing the allergic inflammation per se could have a role
in the regulation of S100A7. FaDu was cultured for 24
h in the absence or presence of IL-4 and histamine fol-
lowed by measurements of S100A7 levels. Both media-
tors markedly repressed the epithelial S100A7 release
(Figure 4).
S100A7 activates PBMC and neutrophils
The last set of experiments aimed to explore the ability of
S100A7 to activate different cellular subsets. The epithe-
lial cell line FaDu, PBMC and neutrophils were stimu-
lated with rhS100A7 for various time points followed by
measurements of cytokine secretion, proliferation and
adhesion molecule expression. In epithelial cells, S100A7
promoted neither IL-6 nor IL-8 secretion after 24 h of
stimulation (data not shown). PBMC, on the other hand,
were induced to release IL-6, IL-8 and IL-10, as well as
proliferate in response to S100A7 (Figure 5A-D). Like-
wise, neutrophils were activated to produce IL-1b,I L - 6
and IL-8, and up-regulate the expression of the adhesion
molecule CD11b (Figure 5E-H).
Discussion
The present study describes S100A7 in the nose and
how it is regulated during SAR. Nasal administration of
LPS induces S100A7 release in healthy non-allergic sub-
jects. Lower levels of S100A7 are seen in NAL fluid
from SAR patients than from healthy controls and the
levels are further decreased upon allergen provocation.
SAR patients having completed ASIT display higher
levels of S100A7 in NAL than before initiation of treat-
ment. S100A7 is found to emanate mainly from the
nasal epithelium and to activate PBMC and neutrophils
to produce cytokines, proliferate and up-regulate adhe-
sion molecule expression. Further, the epithelium-
induced S100A7 generation is repressed by the allergic
mediators IL-4 and histamine.
We have previously identified S100A7 in the NAL
proteome using 2-dimensional gel electrophoresis in
combination with mass spectrometry, and demonstrated
lower levels in patients with symptomatic SAR com-
pared to controls [11]. The present study, investigating
S100A7 in NAL using ELISA, confirms and comple-
ments previous data by showing diminished levels in
SAR patients outside pollen season compared to non-
allergic controls, along with a further reduction in the
SAR group after allergen provocation. Moreover, the
levels appear to return to normal after immunotherapy
treatment. No differences in S100A7 levels among
healthy and allergic subjects are seen in serum, which
supports the notion of a local role for S100A7 in SAR.
Results from immunohistochemical staining and real-
time RT-PCR of nasal biopsies clearly demonstrate pre-
sence of S100A7 in the epithelium and seromucous
glands, and culture of epithelial cells reveals a basal
secretion of S100A7. These findings are in accordance
with a study by Glaser et al. showing an expression in
sebaceous glands in the nose [7], and recent results by
Tieu and colleagues demonstrating reduced levels of
epithelial S100A7 in patients with CRS and SAR [14,15].
It should also be mentioned that in contrast to the low
Figure 4 IL-4 and histamine repress the S100A7 secretion by
epithelial cells. The nasopharyngeal epithelial cell line FaDu was
cultured in the absence or presence of IL-4 (10 ng/ml) or histamine
(10 μM) for 24 h followed by measurements of S100A7 in the
culture supernatants by use of ELISA (n = 6). Data are presented as
mean ± SEM. *, p < 0.05 (paired t-test).
Kvarnhammar et al. Respiratory Research 2012, 13:2
http://respiratory-research.com/content/13/1/2
Page 6 of 10levels of S100A7 seen during inflammatory conditions in
the upper airways, there are studies demonstrating an
enhanced expression and secretion of S100A7 in the
skin of patients with AD [25-27]. Moreover, we have
previously detected S100A7 in tonsillar epithelium and
lymphocytes (CD19
+,C D 4
+ and CD8
+ cells) and found
reduced levels in tonsils in response to infection and
atopic predisposition [12]. In contrast, blood-derived B
and T cells express very low or no levels of S100A7.
These discrepancies in expression might be related to
compartmental differences. Also, the high antigen load
in the tonsils might cause a microbe-induced regulation
of S100A7 expression.
Accumulating evidence suggests that there might be
intrinsic or disease-driven deficiencies in the epithelial
barrier function of the nasal mucosa in AR patients
[28]. Indeed, allergics suffer from an ongoing so called
minimal persistent inflammation, characterized by e.g.
infiltration of inflammatory cells (eosinophils and neu-
trophils) and up-regulation of epithelial adhesion mole-
cules, which in turn primes the nasal mucosa leading to
increased sensitivity and responsiveness to allergen pro-
vocation [29,30]. Likewise, we have recently shown that
SAR patients have higher clinical symptom scores, pul-
monary nitric oxide production, NAL leukocyte
numbers and cytokine levels compared to healthy sub-
jects [16]. The epithelium provides not only a physical
barrier through mucociliary clearance and tight junc-
tions, but it can also resist entry of pathogens through
the production of antimicrobial defense proteins. The
present study shows reduced levels of S100A7 in SAR
patients and in response to allergen challenge. In addi-
tion to the epithelial disruption seen in the atopic airway
[31], we propose defects in AMPs of this kind to be a
factor behind the increased susceptibility to microbial
infection often seen during periods of SAR [32-34].
However, patients having completed ASIT have a less
pronounced minimal persistent inflammation, mani-
fested by a reduced eosinophilic infiltration into the
nasal mucosa and reduced epithelial damage [35], which
in turn can explain the higher levels of S100A7 in NAL
fluid among these patients.
Nasal challenge with LPS, as a mimic of bacterial
upper airway infection, induces release of S100A7 in
NAL fluid from healthy subjects. In line with this, the
expression of S100A7 by the human hair follicle epithe-
lium has been found to be inducible upon treatment
with prototypical microbial products such as LPS [36].
Interestingly, unpublished data from our lab show that
nasal administration of LPS (total dose of 50 μg) in SAR
Figure 5 S100A7 activates PBMC and neutrophils. (A-D) PBMC were cultured (1 × 10
6 cells/ml) for 48 and 72 h with or without S100A7.
Thereafter, cell culture supernatants were analyzed for levels of IL-6, IL-8 and IL-10 by use of ELISA, and the proliferative capacity of the cells was
determined by [methyl-
3H]thymidine incorporation (n = 6). (E-H) Neutrophils were cultured (4 × 10
6 cells/ml) for 4 and 18 h in the absence or
presence of S100A7. Levels of IL-6, IL-8 and IL-1b were measured in the supernatants by ELISA, and expression of CD11b was analyzed by flow
cytometry (n = 6). Data are expressed as mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (ANOVA).
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(before: 92.2 ± 6.5 vs. 24 h after: 92.0 ± 7.4, p = 0.98).
The inability of these patients to respond in terms of
S100A7 secretion might be a consequence of their
impaired antimicrobial defense system. However, it can-
not be excluded that the differential responsiveness to
LPS among healthy and allergic subjects is related to the
dose, as a 2-fold lower concentration was given to the
latter group.
The diminished levels of S100A7 during SAR do not
correlate with the infiltration of neutrophils. Instead, IL-
4 and histamine are found to suppress the S100A7
secretion by epithelial cells, suggesting that a Th2-like
cytokine milieu negatively regulates the S100A7 produc-
tion. Elevated levels of Th2-biased cytokines have been
demonstrated in nasal washings of SAR patients both
during pollen season and after allergen provocation
[37-39], and Glaser et al. have demonstrated that the
TNF-a-induced S100A7 secretion by human keratino-
cytes is inhibited by IL-4 and IL-13 [25].
Even though there is a ~2-fold reduction in the con-
centration of S100A7 in NAL fluid from SAR patients, it
should be mentioned that the changes in levels in some
of the treatment groups are fairly small, which raises
questions regarding the biological significance. However,
in real-life, efficient clearance of microbes involves a
crosstalk between several different cells, signals and
mediators that are triggered simultaneously. This is
reflected by e.g. the ability of S100A7 to activate the cel-
lular immunity and the ability of cytokines, including
TNF-a, IL-4, IL-6 and oncostatin-M [3,25], to both
positively and negatively regulate the generation of
S100A7. Hence, it is not the effect of each single AMP,
but the combined actions of different mediators that are
of biological importance.
The receptor for secreted S100A7 is still unknown,
and consequently its functional relevance is poorly
understood. In the present study, we demonstrate that
S100A7 activates human PBMC and neutrophils to pro-
duce cytokines, proliferate and up-regulate adhesion
molecule expression. Neutrophils have previously been
reported to secrete cytokines, reactive oxygen species
and AMPs in response to S100A7 stimulation [10], but
so far there are no other studies demonstrating an effect
on mononuclear cells except for its chemotactic proper-
ties for CD4
+ T cells [8].
Conclusion
Present data propose that the nasal epithelium produces
S100A7 in response to microbial stimulation, which in
turn attracts immunocompetent cells in order to mount
a proper antimicrobial defense (Figure 6). However, dur-
ing an allergic inflammation, the Th2-type cytokine
response represses the S100A7 release. As a result of
the diminished S100A7 levels, allergic patients have
reduced bactericidal properties as well as a decreased
capability to activate the cellular immunity, which in
turn might render them more susceptible to microbial
colonization and/or make their conditions worse once
an infection is established. In line with this, it is tempt-
ing to speculate that ASIT-treated patients, who have
regained a normal S100A7 production, in turn have a
reduced propensity to develop upper respiratory tract
infections compared to their untreated counterparts.
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